Antibacterial activity and beta-lactamase stability of ceftazidime, an aminothiazolyl cephalosporin potentially active against Pseudomonas aeruginosa.
about
The β-Lactams Strike Back: Ceftazidime-AvibactamComparison of ceftazidime with cefamandole for therapy of community-acquired pneumoniaEvaluation of combination chemotherapy in a lightly anesthetized animal model of Pseudomonas pneumoniaCeftazidime as initial therapy for suspected bacterial infections in hospitalized pediatric patients.Ceftazidime versus tobramycin-ticarcillin in the treatment of pneumonia and bacteremiaComparative activities of piperacillin, ceftazidime, and amikacin, alone and in all possible combinations, against experimental Pseudomonas aeruginosa infections in neutropenic rats.Randomized evaluation of ceftazidime or ticarcillin and tobramycin for the treatment of osteomyelitis caused by gram-negative bacilli.Randomized comparison of ceftazidime versus clindamycin-tobramycin in the treatment of obstetrical and gynecological infections.Comparison of the concentrations of ceftazidime in the serum of newborn infants after intravenous and intramuscular administration.Ceftazidime in the treatment of pediatric patients with severe urinary tract infections due to Pseudomonas sppIn vitro antibacterial activity of the combination of clindamycin and ceftazidimeCeftazidime therapy of serious bacterial infections.Prospective evaluation of effects of broad-spectrum antibiotics on gastrointestinal yeast colonization of humans.Ceftazidime-avibactam (CTZ-AVI) as a treatment for hospitalized adult patients with complicated intra-abdominal infections.Cephalosporins in cutaneous infections. A prospective comparison of two dosage regimens of ceftazidime for therapy of skin and skin structure infections.Enhancing effect of serum ultrafiltrate on the activity of cephalosporins against gram-negative bacilli.Effects of broad-spectrum antimicrobial agents on yeast colonization of the gastrointestinal tracts of miceAntimicrobial activity, pharmacokinetics, therapeutic indications and adverse reactions of ceftazidime.In vitro comparison of Pseudomonas aeruginosa isolates with various susceptibilities to aminoglycosides and ten beta-lactam antibiotics.High-pressure liquid chromatographic analysis of ceftazidime in serum and urine.Pharmacokinetics and bacteriological effect of ceftazidime in experimental Streptococcus pneumoniae, Haemophilus influenzae, and Escherichia coli meningitis.Rationale for eliminating Staphylococcus breakpoints for β-lactam agents other than penicillin, oxacillin or cefoxitin, and ceftaroline.In-vitro activity of ciprofloxacin and sixteen other antimicrobial agents against blood culture isolates.A comparative study on aztreonam, ceftazidime and amikacin in the treatment of complicated urinary tract infections.
P2860
Q26796425-D4A70CFA-265D-423F-9A11-38FF9BB42FD8Q30451309-236B140C-93C2-419F-806C-096EDA38C5A3Q35537663-94F5D768-ED43-497E-A663-42584BA7DD9DQ35568218-70E249CD-B23D-4E7B-B783-37C6720E60A7Q35571259-97281A67-2692-4078-B837-4A0FED9DF407Q35647858-930CACF5-799A-49F6-88A2-0FDBB333204CQ35648514-0ABF4333-AA91-4E05-BBD9-405A30A74FE8Q35754923-4F6EF8F4-B47A-49EF-A1AB-A141D4872D6CQ35755881-D8EA3E00-A0D8-425B-8C19-E3AF94E6BF9FQ35758350-AC52BA1E-99E7-438D-97A4-B5ACDB2461D9Q35760281-71CC4D0F-BADB-4A8C-A7A7-665975E6C803Q35769557-66BFB6D3-1737-4A2E-87D6-9C9FFC67279CQ35807561-A30C1235-C85E-4EEF-AF4C-EEE0A0E1B141Q38797485-5B45EE6A-94F5-4E9D-9B19-F61EDF9792B2Q39104856-E3F12F63-E3D9-461B-AB07-53782B783E87Q39814757-534BD9D3-643A-45EC-8D22-046E6518DEFDQ39817374-14B46584-D084-4C61-8F69-BF1AFAB58D49Q39835738-4A74F456-BABF-49D1-B1DB-D72B69FAAA33Q41879116-E5BEC50A-02FD-4E2B-91A3-95CB8C1EE2A9Q42111249-0A7D38A2-D42E-419D-B210-DD23D86DD0E4Q42129227-CC9C356F-D5AD-4652-B39F-E2FE39DB9CD6Q44566052-E4079DAD-348B-47C9-9240-CABBDAADF330Q50164239-32006606-5064-445D-999D-C63B925DF7F4Q54687938-8C45B874-665B-41FC-9B99-ED96C96E2B99
P2860
Antibacterial activity and beta-lactamase stability of ceftazidime, an aminothiazolyl cephalosporin potentially active against Pseudomonas aeruginosa.
description
1982 nî lūn-bûn
@nan
1982年の論文
@ja
1982年論文
@yue
1982年論文
@zh-hant
1982年論文
@zh-hk
1982年論文
@zh-mo
1982年論文
@zh-tw
1982年论文
@wuu
1982年论文
@zh
1982年论文
@zh-cn
name
Antibacterial activity and bet ...... gainst Pseudomonas aeruginosa.
@en
Antibacterial activity and bet ...... gainst Pseudomonas aeruginosa.
@nl
type
label
Antibacterial activity and bet ...... gainst Pseudomonas aeruginosa.
@en
Antibacterial activity and bet ...... gainst Pseudomonas aeruginosa.
@nl
prefLabel
Antibacterial activity and bet ...... gainst Pseudomonas aeruginosa.
@en
Antibacterial activity and bet ...... gainst Pseudomonas aeruginosa.
@nl
P2860
P356
P1476
Antibacterial activity and bet ...... gainst Pseudomonas aeruginosa.
@en
P2093
P2860
P356
10.1128/AAC.21.1.11
P407
P577
1982-01-01T00:00:00Z